In a retrospective analysis of the adjuvant trastuzumab trial N9831 recently published in the Journal, Perez et al . ( 1 ) ( 2 ) . They concluded that the FDA, rather than ASCO/CAP criteria should be used to determine the eligibility of breast cancer patients for trastuzumab adjuvant therapy. Indeed, this recommendation is not dissimilar from the original recommendations of the ASCO/ CAP HER2 Testing Panel ( 3 , 4 ) . The Panel recommended that "equivocal" categories be established for HER2 that were meant to trigger HER2 reflex testing using another appropriately validated assay platform such as fluorescent in situ hybridization (FISH) if immunohistochemical (IHC) staining for HER2 was equivocal or with IHC if FISH results were equivocal. In this regard, the ASCO/CAP Panel recommended that the percentage of cells with strong uniform membrane staining by IHC required to deem a case 3+ be increased from the 10% used in the FDA eligibility requirements to 30% and that 11% -29% should be considered equivocal and trigger confirmatory FISH testing. The Panel also recommended routine proficiency testing, which has since been widely adopted by the pathology community as shown by the uptake since the year 2007 in the numbers of labs in the United States and elsewhere participating in predictive marker proficiency testing as part of the College of American Pathologists Laboratory Improvement Program ( Figure 1 ) ( 5 ). Overall, the Panel felt that this strategy would provide clinicians and patients with additional confidence as eligibility for adjuvant trastuzumab was determined ( 4 ). However, in their report, Perez et al. state that on the basis of their retrospective assessment of the N9831 trial, "up to approximately 4% of patients may miss receiving a recommendation to receive adjuvant trastuzumab, depending on the testing done, if the ASCO/CAP vs the FDA cutoffs for HER2 positivity are used" ( 1 ). Although we agree that undertreatment of patients with trastuzumab is problematic, we do not feel this estimate is accurate. A 4% undertreatment would only occur if the HER2 guideline recommendations for refl ex testing are ignored. Indeed, Perez et al. state that "determining HER2 positivity on the basis of both IHC and FISH results vs either IHC or FISH alone decreases the number of ineligible patients and decreases the number of false-negative results." To be more specifi c, 107 patients in N9831 had tumors for which more than 10% -30% of cells had 3+ membrane staining by IHC ( 1 ). These patients were eligible by FDA criteria for N9831 but would now be considered equivocal per ASCO/ CAP criteria. Of the 100 patients then also tested by FISH, 78 had a FISH HER2/ CEP17 ratio of more than 2.2 and would have been deemed HER2 positive by ASCO/CAP criteria. Thus, the remaining 22 patients (22% of the 100 IHC equivocal patients, but 0.78% of the entire 2809 patients with dual testing in N9831) would be considered HER2 negative by ASCO/ CAP criteria. Conversely, if FISH were the primary test, 37 patients had equivocal ASCO/CAP criteria ratios of 2.0 to 2.2. When tested by IHC, six (16%) would have been IHC 3+ with greater than 30% strong membrane staining and confi rmed HER2 positive by ASCO/CAP criteria, whereas 31 (84% of FISH equivocal, but 1.1% of the 2809 patients with dual testing) had tumors that had ASCO/CAP equivocal IHC 3+ staining in more than 10% but less than 30% of cells and would thus be considered HER2 negative. Assuming a HER2 overexpression frequency of 15% in the general population of newly diagnosed breast cancer patients, we estimate that approximately 0.15% of all patients would fall into the category of undertreatment using ASCO/CAP guidelines compared with FDA trial eligibility criteria.
Given the remarkable reduction in recurrence and mortality offered by adjuvant trastuzumab, the ASCO/CAP HER2 Panel does not take lightly that its criteria might have led to undertreatment of up to 1.1% of patients with HER2-positive tumors that otherwise met criteria for trial N9831. However, in a separate article describing a HER2 testing round robin study, Dr Perez et al. ( 6 ) reported that, despite excellent concordance, the overall discordance for IHC and FISH testing among international experts were 4% and 3%, respectively, which exceeds the 1% reported in the current analysis ( 1 ) . Those data highlight persistent issues of assay interpretation, tumor heterogeneity, and platform robustness, even among experts in the fi eld, which continue to challenge HER2 testing in daily practice.
Nonetheless, it is reassuring that the concordance between local testing in laboratories throughout the United States and confi rmatory central HER2 testing at the Mayo Clinic (Rochester, MN) for the recently completed Adjuvant Lapatinib and/ or Trastuzumab Treatment Optimisation HER2 adjuvant trial showed that only approximately 5.8% of patients initially deemed eligible were not centrally confi rmed to be HER2 positive ( 7 ) . This is substantially lower than the cumulative HER2 false-positive rates ultimately reported for trial N9831 of 18% (IHC) and 12% (FISH) ( 8 ) . These results suggest progress in standardizing HER2 testing, in part , because of greater attention to preanalytic and analytic factors, which we believe results from the implementation of routine profi ciency testing since early 2007, and reinforce the potential critical value of ongoing efforts by organizations like ASCO and CAP and the practical benefi t of providing access to high-quality predictive biomarker testing to all patients everywhere. Nonetheless, the issue of equivocal test results will be carefully considered in a planned upcoming update of the HER2 Testing Guideline along with evidence on the current frequency of this occurrence following guideline implementation.
